|
Hydrocortamate
|
DB00769 |
[Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects.] |
|
Clavulanic acid
|
DB00766 |
[Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections.[T665] Clavulanic acid is derived from the organism Streptomyces clavuligerus.[A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910]] |
|
Metyrosine
|
DB00765 |
[An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)] |
|
Olopatadine
|
DB00768 |
[Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of [doxepin], which has a minimal anti-allergic activity.[L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions. An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.[A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.[A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations. It is currently marketed under several brand names, including Pazeo, Patanase, and Opatanol.] |
|
Benzquinamide
|
DB00767 |
[Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors. ] |
|
Irinotecan
|
DB00762 |
[Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).] |
|
Potassium chloride
|
DB00761 |
[A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.] |
|
Mometasone
|
DB00764 |
[Mometasone is a medium-potency synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.] |
|
Methimazole
|
DB00763 |
[Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate[L8336,L8339].
On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [Propylthiouracil],[L8339] and is the active metabolite of the pro-drug [Carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth.[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a perceived lower risk of teratogenic effects. Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in the future.] |
|
Meropenem
|
DB00760 |
[Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.] |
|
MSX-122
|
DB12715 |
[MSX-122 has been used in trials studying the treatment of Solid Tumors.] |
|
NB-001
|
DB12716 |
[NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.] |
|
Mibampator
|
DB12717 |
[Mibampator has been used in trials studying the treatment of Alzheimer's Disease.] |
|
Carlumab
|
DB12718 |
[Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.] |
|
LTX-109
|
DB12711 |
[LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.] |
|
Pilsicainide
|
DB12712 |
[Pilsicainide has been investigated for the treatment of Paroxysmal Atrial Fibrillation.] |
|
Sotagliflozin
|
DB12713 |
[Sotagliflozin has been used in trials studying the treatment of Renal impairment, Hepatic Impairment, Type 1 Diabetes Mellitus, and High Level of Sugar (Glucose) in the Blood.] |
|
Nerispirdine
|
DB12714 |
[Nerispirdine has been used in trials studying the treatment of Neuritis, Optic Nerve, and Multiple Sclerosis.] |
|
Perazine
|
DB12710 |
[Perazine has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.] |
|
Meclizine
|
DB00737 |
[Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects.[L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.] |